New Study Shows AssuriTEA Improves Lower Urinary Tracts Symptoms in Men

DES MOINES, Iowa—Kemin announced the publication of a clinical study conducted by Aaron Katz, M.D., chairman of urology at Winthrop University Hospital. The study found that daily use of 1,000 mg of AssuriTEA, a patent-pending polyphenol blend of catechins and theaflavins, improved lower urinary tract symptoms (LUTS) and quality of life in men in as little as six weeks (Ther Adv Urol  doi:10.1177/1756287214526924).

“This study is significant because it is the first of its kind to show the measurable, urological benefits of combining specific quantities of catechins and theaflavins,"  Katz said. “LUTS is one of the most common urologic conditions, affecting a majority of adult men as they age. Currently, some of the alternative nutritional-based approaches for managing men’s urinary function and comfort lack supporting scientific evidence."

The randomized, double blind, placebo-controlled study, conducted over 12 weeks with 40 participants completing the study, showed improvement in LUTS and showed decreases in post-void residual volume, increases in average urinary flow rate and improvements in quality of life as well as moderation of inflammation. No gastrointestinal distress or other negative side effects were reported.

“We are excited about the publication of the men’s health clinical study, which validates the hard work and comprehensive research on this unique, patent-pending ingredient," said Jeff Flora, president of the human nutrition and health division of Kemin. “Improving urinary health is a top concern of older males, and we believe men can continue to enjoy an active lifestyle and maintain their quality of life using products that contain our AssuriTEA nutritional ingredient."

AssuriTEA is an all-natural ingredient that uses water-extraction to ensure high levels of select polyphenols. It is generally recognized as safe (GRAS) for certain food and beverage applications. Clinical findings on the antioxidant benefits of AssuriTEA are expected to be published later this year.